ZZZhen Zhang

Zhen Zhang

*This is an algorithmically generated author record based on publicly available information.

Zhen Zhang has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metastable Protein–Protein Interactions as a Design Principle for PROTACs: Insights from the RIPK1–VHL System

    by Yue Wu, Zhen Zhang, Nina J. Hawkins, Weiping Tang, Xuhui Huang

    Proteolysis-Targeting Chimeras (PROTACs) eliminate disease-relevant proteins by stabilizing short-lived, metastable protein–protein interactions (PPIs) between a target protein and an E3 ligase. These transient encounter complexes are central to PROTAC activity, yet they are difficult to predict and are often invisible to structure-based or AI-only modeling approaches that favor stable, native interactions. Here, we show that explicitly accounting for metastable PPIs provides an effective design principle for rational PROTAC development. Using large-scale molecular dynamics (MD) simulations combined with integrative generalized master equation (IGME) modeling, we mapped the ensemble of metastable PPIs between receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and the von Hippel-Lindau (VHL) E3 ligase, and identified four distinct PPIs suitable for degrader engagement. We find that different PPIs preferentially accommodate different linker architectures, providing a mechanistic explanation for the counterintuitive experimental observation that PROTACs with very short and very long linkers can consistently yield potent degradation. Guided by this insight, we established a virtual screening workflow for linker design and identified the benzylic position on the VHL ligand as a viable linkage site. Rationally designed novel PROTACs featuring this site achieve complete degradation with subnanomolar to low-nanomolar potency. Our results demonstrate that incorporating protein dynamics into degrader design substantially expands the accessible PROTAC design space.

  • Open Access

    Metastable Protein-Protein Interactions as a Design Principle for PROTACs: Insights from the RIPK1-VHL System

    by Yue Wu, Zhen Zhang, Nina Josephine Hawkins, Weiping Tang, Xuhui Huang

    Proteolysis-targeting chimeras (PROTACs) eliminate disease-relevant proteins by stabilizing shortlived, metastable protein-protein interactions (PPIs) between a target protein and an E3 ligase. These transient encounter complexes are central to PROTAC activity, yet they are difficult to predict and are often invisible to structure-based or AI-only modeling approaches that favor stable, native interactions. Here, we show that explicitly accounting for metastable PPIs provides an effective design principle for rational PROTAC development. Using large-scale molecular dynamics (MD) simulations combined with integrative generalized master equation (IGME) modeling, we mapped the ensemble of metastable PPIs between receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and the von Hippel-Lindau (VHL) E3 ligase, and identified four distinct PPIs suitable for degrader engagement. We find that different PPIs preferentially accommodate different linker architectures, providing a mechanistic explanation for the counterintuitive experimental observation that PROTACs with very short and very long linkers can consistently yield potent degradation. Guided by this insight, we established a virtual screening workflow for linker design and identified the benzylic position on the VHL ligand as a viable linkage site. Rationally designed novel PROTACs featuring this site achieve complete degradation with sub-nanomolar to low-nanomolar potency. Our results demonstrate that incorporating protein dynamics into degrader design substantially expands the accessible PROTAC design space.

  • Open Access

    Development of Potent and Selective RIPK1 Degraders Targeting Its Nonenzymatic Function for Cancer Treatment

    by Zhen Zhang, Chunrong Li, Nina J. Hawkins, Ramesh Mudududdla, Yiming Nie, Peng-Kai Liu, Penghsuan Huang, Natalia M. Del Rio, Hao Chang, Matthew E. Brown, et al.

    Receptor-interacting protein kinase 1 (RIPK1) is a threonine/serine kinase that serves as a critical regulator of immune responses and cell death pathways, functioning through both its kinase activity and nonenzymatic scaffolding function. The scaffolding function of RIPK1 contributes to both intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), making it a compelling therapeutic target for cancer treatment. Recent studies have highlighted RIPK1's potential as a key modulator for improving the efficacy of immune-stimulatory therapies, such as ICBs and X-ray radiotherapy (XRT). In this study, we have developed a highly potent and selective RIPK1 degrader. When combined with XRT, the degrader significantly suppressed tumor growth, achieving enhanced therapeutic efficacy without apparent adverse effects. In contrast, the RIPK1 inhibitor showed no notable therapeutic effect. These findings underscore the potential of targeting RIPK1 degradation, specifically its nonenzymatic function, as a novel strategy to augment the effects of radiotherapy.


  • Synthesis of the 5/5-spiroindimicin alkaloids: development of a general synthetic approach and biological investigations

    by Ankush Banerjee, Tiffany A. Brisco, Sneha Ray, Arani Datta, Xiaoyu Zhang, Zhen Zhang, Alexander A. Busse, Hanspeter Niederstrasser, Krissty Sumida, Bruce A. Posner, et al.

    We describe the development of a unified synthetic strategy for the preparation of all known 5/5-spirocyclic spiroindimicin (SPM) alkaloids, namely spiroindimicins B–G. The present synthetic route relies on four fundamental transformations: Grignard-based fragment coupling between halogenated pyrrolemetal and isatin partners, Suzuki coupling to generate a triaryl scaffold encompassing all requisite skeletal atoms of the natural products, Lewis acid-mediated spirocyclization to construct the 5/5-spirocyclic core, and chemoselective lactam reduction. The developed syntheses are step-economic (6–7 steps from commercial materials), scalable, and amenable to analogue synthesis. Preliminary investigations into a catalytic asymmetric spirocyclization towards an enantioselective SPM synthesis are also described. Further studies of the antiparasitic properties of this class have revealed promising activity against T. brucei for certain congeners. Together with our prior approach to the 6/5-family members, our work constitutes a synthetic solution to all known spiroindimicin natural products.

  • Modular Total Synthesis of the 5/5-Spirocyclic Spiroindimicins

    by Ankush Banerjee, Tiffany A. Brisco, Zhen Zhang, Alexander A. Busse, Krissty Sumida, Myles W. Smith

    Total syntheses of the 5/5-spirocyclic indoline alkaloids (±)-spiroindimicins B, C, D, E, F, and G have been achieved via a modular approach. Our route features direct coupling of halogenated pyrrolemetal and isatin partners, Suzuki coupling to append the indole unit, Lewis acid-mediated spirocyclization, and divergent functionalization to give various family members. These syntheses are concise (six or seven steps from commercial materials) and highly amenable to analogue synthesis.


  • Abstract LB205: The IRF8-MEF2D transcription factor circuit regulated by a druggable multiple post-translational modification (PTM) reader ZMYND8 in acute myeloid leukemia

    by Zhendong Cao, Krista A. Budinich, Hua Huang, Bin Lu, Zhen Zhang, Diqiu Ren, Yeqiao Zhou, Yuhan Huang, Bianca Pingul, Molly C. Kingsley, et al.

    The transformed state in acute leukemia requires gene regulatory programs involving transcription factors (TFs) and chromatin modulators. Here, we uncover an IRF8-MEF2D TF regulatory circuit as an acute myeloid leukemia (AML)-specific dependency. We discover and characterize the mechanism by which the chromatin ‘reader' ZMYND8 directly activates IRF8 in parallel with the MYC proto-oncogene through their AML-specific enhancers. ZMYND8 is essential for AML proliferation in vitro and in vivo and associates with MYC and IRF8 enhancer elements that we define in cell lines and in patient samples. ZMYND8 occupancy at IRF8 and MYC enhancers requires BRD4, a transcriptional coactivator essential for AML proliferation. We show that ZMYND8 binds to the ET domain of BRD4 via its chromatin reader cassette, which in turn is required for proper chromatin occupancy and maintenance of leukemic growth in vivo. Our results rationalize ZMYND8 as a potential selective therapeutic target for modulating essential transcriptional programs in AML. Citation Format: Zhendong Cao, Krista A. Budinich, Hua Huang, Bin Lu, Zhen Zhang, Diqiu Ren, Yeqiao Zhou, Yuhan Huang, Bianca Pingul, Molly C. Kingsley, Alexandra K. Lenard, Jun Qi, Martin P. Carroll, Gerd A. Blobel, Robert B. Faryabi, Kathrin M. Bernt, Shelley L. Berger, Junwei Shi. The IRF8-MEF2D transcription factor circuit regulated by a druggable multiple post-translational modification (PTM) reader ZMYND8 in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB205.

  • Open Access

    Total synthesis of (+)-spiroindimicin A and congeners unveils their antiparasitic activity

    by Zhen Zhang, Sneha Ray, Leah Imlay, Lauren T. Callaghan, Hanspeter Niederstrasser, Prema Latha Mallipeddi, Bruce A. Posner, Dawn M. Wetzel, Margaret A. Phillips, Myles W. Smith

    Spiroindimicins A and H have been synthesized for the first time via a key palladium-catalyzed spirocyclization. Access to these alkaloids and several congeners has allowed the discovery of their antiparasitic properties.


  • Open Access

    Total Synthesis of (+)-Spiroindimicin A via Asymmetric Palladium-Catalyzed Spirocyclization

    by Zhen Zhang, Sneha Ray, Leah Imlay, Lauren Callaghan, Hanspeter Niederstrasser, Prema Latha Mallipeddi, Bruce A. Posner, Dawn Wetzel, Margaret Phillips, Myles Smith

    The spiroindimicins are a unique class of chlorinated indole alkaloids characterized by three heteroaromatic rings structured around a congested spirocyclic stereocenter. Here, we report the first total synthesis of (+)-spiroindimicin A, which bears a challenging C-3’/C-5’’-linked spiroindolenine. We detail our initial efforts to effect a biomimetic oxidative spirocyclization from its proposed natural precursor, lynamicin D, and describe how these studies shaped our final abiotic 9-step solution to this complex alkaloid built around a key asymmetric Pd-catalyzed spirocyclization. Scalable access to spiroindimicins A, H, and their congeners has enabled discovery of their activity against several parasites relevant to human health, providing potential starting points for new therapeutics for the neglected tropical diseases leishmaniasis and African sleeping sickness.

  • Enantioselective Total Synthesis of (+)-Arboridinine

    by Zhen Zhang, Sujun Xie, Bin Cheng, Hongbin Zhai, Yun Li

    The enantioselective total synthesis of cage-shape alkaloid (+)-arboridinine is reported. The synthesis takes advantage of stereoselec-tive double-Mannich reaction to rapidly construct the aza[3.3.1]bicyclic core along with two quaternary stereocenters of the alkaloid. Key steps for the present synthesis include an enantioselective Michael addition establishing the original chiral center at C10, and intramolecular dearomative alkylation forging the cage-shape ring system found in arboridinine, as well as creating the requisite qua-ternary carbon center at C3. The bridgehead hydroxyl moiety at C11 was installed through a late-stage cobalt-catalyzed decarboxyla-tive acetoxylation reaction. This strategy enables a 14-step asymmetric total synthesis of (+)-arboridinine from the readily available starting materials with most of the transformations performed on the decagram scale.


  • Total Synthesis of the Diterpenoid (+)‐Harringtonolide

    by Hai‐Jun Zhang, Lin Hu, Zhiqiang Ma, Ruining Li, Zhen Zhang, Cheng Tao, Bin Cheng, Yun Li, Huifei Wang, Hongbin Zhai

    Described herein is the first asymmetric total synthesis of (+)‐harringtonolide, a natural diterpenoid with an unusual tropone imbedded in a cagelike framework. The key transformations include an intramolecular Diels–Alder reaction and a rhodium‐complex‐catalyzed intramolecular [3+2] cycloaddition to install the tetracyclic core as well as a highly efficient tropone formation.